Publications

Real-World Data On Patients’ Characteristics Guiding Physicians’ Choice Of First-line Treatment For Advanced Urothelial Carcinoma: Is There Still A Place For Platinum-based Chemotherapy?

Real-world Sequencing of Anti-bcma Car T-cells and Bispecific T-cell Engagers in Relapsed/refractory Multiple Myeloma: a Multi-country Analysis

Iron deficiency treatment pathway in Italy: patients’ perceptions of diagnosis and treatment.

Biologic treatment patterns and phenotyping in severe uncontrolled asthma: a multinational study.

Definitive staging and perioperative treatment for resectable Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC) a UK perspective.

Understanding ALK+ NSCLC caregivers’ psychosociological burden: Findings from the study ‘‘Living with ALK+ cancer in France’’

Real-world data on the management of potentially resectable stage IB-IIIA non-small cell lung cancer (NSCLC) in the United Kingdom (UK) in 2023: Early adoption of immune checkpoint inhibitors (ICIs).

Experiences of patients with advanced ALK+ non-small-cell lung cancer (NSCLC) in France: results of the qualitative phase of the “Living with ALK+ cancer” survey. Qualitative study conducted by APLUSA.

Real world treatment of newly diagnosed patients with acute myeloid leukemia and aged between 60 and 75 years. Analysis of key drivers for chemotherapy selection in France and Germany.

Current use of BCMA-targeted agents in relapsed/refractory multiple myeloma and key drivers when selecting CAR-T cells versus bispecifics. Data from real-world study in EU5 countries and in the US.